Title: Radiological Response Assessment in High Grade Gliomas: 3DCRT vs IMRT
Authors: Dr Rahul Loni, Dr Chaitanya S, Dr Poojar Sridhar, Dr Naveen T, Dr Ibrahim Khaleel, Dr K.P.R. Pramod, Dr Lokesh V
DOI: https://dx.doi.org/10.18535/jmscr/v5i8.161
Abstract
Objectives: To compare the radiological response in high grade glioma patients receiving post-operative radiation therapy via 3DCRT /IMRT technique with concurrent and adjuvant temozolomide.
Materials and Methods: Twenty newly diagnosed histologically proven patients of high grade glioma in the age group of 18-70 years, post maximal resection were recruited and all patients received concurrent chemo-irradiation followed by adjuvant chemotherapy. All patients received a dose of 60 Gy in 30 fractions via 3DCRT/IMRT technique along with concurrent and adjuvant temozolomide according to Stupp’s regimen. Radiological response was assessed using Cho:NAA ratio in magnetic resonance spectroscopy done at 0,4th and 14th week of radiation therapy.
Results: There was no statistically significant difference in the post radiation therapy radiological response with respect to Cho:NAA ratio between the 2 groups suggesting similar outcomes when high grade gliomas are treated with 3DCRT / IMRT technique.
Conclusion: In patients diagnosed with high grade glioma treated by post-operative radiation therapy with concurrent and adjuvant temozolomide, radiation therapy can be delivered either with 3DCRT or IMRT technique without compromise in radiological response to treatment.
Keywords: Intensity Modulated Radiation Therapy (IMRT), 3D Conformal Radiation Therapy (3DCRT), Temozolomide, MRS (Magnetic Resonance Spectroscopy), glioma.
References
- Weller M. Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly.141:w13210
- Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol. 2003 Dec; 30(6 Suppl 19):4-9.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10; 352(10):987-96.
- Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol Assoc Pol Neuropathol Med Res Cent Pol Acad Sci. 2010;48(2):81–92.
- Nieder C andratschke N, Price RE, Rivera B, Ang KK. Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Res. 2002 Apr;22(2A):1017–23.
- Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, et al. Malignant gliomas: MR imaging spectrum of radiation therapy and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000 Nov; 217(2):377–84.
- Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol. 2009 Feb;192(2):W45–52.
- Sabry A. Elmogy AEM. MR spectroscopy in post-treatment follows up of brain tumors. Egypt J Radiol Nucl Med. 2011;42(s 3–4):413–24.
- Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer S, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol. 2005 Dec;185(6):1471–6.
- Schlemmer H-P, Bachert P, Herfarth KK, Zuna I, Debus J, Kaick G van. Proton MR Spectroscopic Evaluation of Suspicious Brain Lesions After Stereotactic Radiotherapy. Am J Neuroradiol. 2001 Aug 1;22(7):1316–24.
- Schlemmer HP, Bachert P, Henze M, Buslei R, Herfarth KK, Debus J, et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology. 2002 Mar;44(3):216–22.
- Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., ... Chang, S. M. (2010). Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. Journal of Clinical Oncology, 28(11), 1963-1972. DOI: 10.1200/JCO.2009.26.3541
- Magnetic Resonance Spectroscopy for Differentiating Pseudo-Progression from True Progression in GBM on Concurrent Chemoradiotherapy V. Sawlani, R. Taylor, K. Rowley, R. Redfern, J. Martin, H. Poptani
- Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery. 1994 Oct; 35(4):606–13; discussion 613–4.
- Kuesel AC, Sutherland GR, Halliday W, Smith IC. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994 May;7(3):149–55.
- Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci Off J Soc Neurosci. 1993 Mar;13(3):981–9.
- Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh GR, Cosgrove GR, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology. 2002 Dec;225(3):871–9.
- Kaminaga T, Shirai K. Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy. J Comput Assist Tomogr. 2005 Jun;29(3):293–7.
- MACDONALD, Shannon M et al. Intensity Modulated Radiation Therapy (IMRT) Versus Three Dimensional Conformal Radiation Therapy (3DCRT) for the Treatment of High Grade Glioma: A Dosimetric Comparison. Journal of Applied Clinical Medical Physics, [S.l.], v. 8, n. 2, apr. 2007. ISSN 15269914.
- Chan MF, Schupak K, Burman C, et al. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim. 2003;28(4):261265.